Navigation Links
Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
Date:11/25/2008

MONTREAL, Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral presentation at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, on December 9, 2008.

The presentation is entitled "Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML". The trial was an open label, multi-center study evaluating the safety and efficacy of AEG35156 in combination with chemotherapy in AML patients in first relapse after a short initial CR or with primary refractory disease. A total of 51 patients were enrolled in the study. The results demonstrate that AEG35156 is well tolerated at 350 mg/m2 in combination with idarubicin and cytarabine. The results also support the finding that AEG35156 combination therapy may induce high response rates in AML patients not responding to frontline induction therapy. Updated results on additional patients will be presented at the ASH Annual Meeting.

The study's principal investigator, Dr. Aaron D. Schimmer, M.D., Ph.D. of the Princess Margaret Hospital in Toronto will present the results of this study at the ASH session entitled "Acute Myeloid Leukemia - Therapy, Excluding Transplantation".

In addition, PD data from the same study will be presented by Dr. Carter Bing of the MD Anderson Cancer Center in a poster on December 7 under the title "Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML".

Details of each of these presentations are listed below.

2008 ASH Annual Meeting ASH - Oral Presentation

Title: Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156)

in Co
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
2. Aegera Therapeutics welcomes two experienced executives to its board of directors
3. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
4. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
5. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
6. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
7. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...vember 6, 2009 As global temperatures and energy ...y will be key to a sustainable future. An attrac...wo studies published online in Genome Research (...nome structures of bioethanol-producing microorgan...al in developing new technologies needed to implem...
(Date:11/6/2009)..., TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Microbi...that it has re-filed the Form 52-109F1 Certificati...Executive Officer and James Long, the Chief Financ...anuary 12, 2009 in connection with the annual audi...ber 30, 2008. ,, The Company initially filed th...
(Date:11/6/2009)..., QUINCY, Mass., Nov. 6 Myriant Te...ech developer and manufacturer of renewable bio-c...erred technology provider Uhde GmbH, one of the wo...de"), announced an alliance for the engineering, p...iobased Succinic Acid plants based on renewable fe...
(Date:11/6/2009)..., SPRING VALLEY, Calif., Nov. 6 Ca...arded a Small Business Innovative Research (SBIR) ... and Material command. Under terms of the agreemen...ts (ASRs) for the diagnosis of Dengue virus. ,...t represents a major threat to military forces dep...
Breaking Biology Technology:Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2
...KEE-- NuEdge Systems , an Experian company providi...d NuEdge Suite 3.0. , ,NuEdge Suite allows compan...sumer interactions: fickle buying patterns, multi-...Suite 3.0 features: , , A data mart built from un... customer accounts, teller/POS interfaces, Web sit...
...ors Note: John Pulling, Provia,s vice president a...the Auto-ID Center, the independent organization t...Code (EPC) Technology Network, which links serial ...e. Provia Software is a Michigan-based warehouse...io frequency identification tagging (RFID). The co...
...KEE-- Hal Leonard Corporation , (HLC) headquarter...ublisher, and MakeMusic! Inc. , the leading music...t will be bundling SmartMusic with HLCs popular bo...ts 2000 for Band Book 1 and Essential Elements 200...-based music practice system with over 20,000 fun ...
Other Biology Technology:WTN Interview: John Pulling, Provia Software
Hitting the Wal-Mart RFID Deadline 2WTN Interview: John Pulling, Provia Software
Hitting the Wal-Mart RFID Deadline 3
(Date:11/4/2009)... has received more than $10 million in research gr...eral stimulus program, bringing thetotal amount of...3 million. Thirty-three projects achieved stimulu...weather. , "The university has thoughtfully unde...cholarly excellence to federal agency priorities. ...
(Date:11/4/2009).../ -- What,s the cost of saving a teenage life? Whe...g from prescription medication abuse, there,s no p...ay be unaware that the lock-boxes they,ve installe...timebomb of prescription drugs. That,s why MEDNET(...supplies, has formed an exclusive partnership with...
(Date:11/4/2009)...wire/ -- GenVault Corporation (Carlsbad, CA) today...ined its Board of Directors. Dr. Brody, the Irwin...is an acclaimed physician-scientist and university... Brody served as president of The Johns Hopkins Un...of Engineering and the Institute of Medicine, and ...
Breaking Biology News(10 mins):OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 14171 1Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 14171 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 14171 3Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 14171 4New Productivity Suite From Varian Inc Increases Throughput for NMR Laboratories 14169 1New Productivity Suite From Varian Inc Increases Throughput for NMR Laboratories 14169 2New Productivity Suite From Varian Inc Increases Throughput for NMR Laboratories 14169 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 1DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 2DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 4DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 6
... starship Enterprise would deploy a deflector shie...of switching on a molecular force field of their o...ow University of Florida researchers have found a ...yme that bonds with a protein, creating a protecti...chemotherapy and promotes tumor cell survival. But...
... high levels of antibodies against the Epstein-Bar...eosis, may be more likely to develop multiple scle...osted online today that will appear in the June 20...e JAMA/Archives journals. , Researchers have long ...risk for multiple sclerosis (MS), a chronic autoim...
...T have found a new way of looking beneath the ocea...hether fish populations are shrinking. , A remote ...holas Makris of mechanical engineering, along with...val Research Laboratory, allows scientists to trac... small schools, over a 10,000-square-kilometer are...
Other Biology News:Molecular force field helps cancer cells defend against attack 2Molecular force field helps cancer cells defend against attack 3Big hips, big belly? It's in your genes, Joslin-led study shows 2One fish, two fish: New MIT sensor improves fish counts 2
... belong to the transforming growth factor- (TGF-) ... of extra-cellular growth factors which control ma...nd tumor formation (1). Other members incude TGF-s...ion factors, AMH/MIS (Anti-Mullerian Hormone/Mulle...
...ng in just seconds , No need for glass rods and ...rm spreading and more colonies, Two choices of re... spreading 100 plates or single-use tubes for 50 p...on multiple plates simultaneously ,EZ-Spread Pla...
Silencer siRNA Starter Kit from Ambion
... environment, Pipette Tracker Pro is the only pipe...c pipette calibration and record keeping within a ...requirements. Pipette Tracker Pro is a secure solu... support for Oracle and SQL Server databases, meth...
Biology Products: